{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:45:08Z","timestamp":1790534708528,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["805498"],"award-info":[{"award-number":["805498"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2017\/27\/B\/HS1\/00290"],"award-info":[{"award-number":["2017\/27\/B\/HS1\/00290"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001870","name":"Fundacja na rzecz Nauki Polskiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HPLS"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current strategy of searching for an effective treatment for COVID-19 relies mainly on repurposing existing therapies developed to target other diseases. Conflicting results have emerged in regard to the efficacy of several tested compounds but later results were negative. The number of conducted and ongoing trials and the urgent need for a treatment pose the risk that false-positive results will be incorrectly interpreted as evidence for treatments\u2019 efficacy and a ground for drug approval. Our purpose is twofold. First, we show that the number of drug-repurposing trials can explain the false-positive results. Second, we assess the evidence for treatments\u2019 efficacy from the perspective of evidential pluralism and argue that considering mechanistic evidence is particularly needed in cases when the evidence from clinical trials is conflicting or of low quality. Our analysis is an application of the program of Evidence Based Medicine Plus (EBM+) to the drug repurposing trials for COVID. Our study shows that if decision-makers applied EBM+, authorizing the use of ineffective treatments would be less likely. We analyze the example of trials assessing the efficacy of hydroxychloroquine as a treatment for COVID-19 and mechanistic evidence in favor of and against its therapeutic power to draw a lesson for decision-makers and drug agencies on how excessive hypothesis testing can lead to spurious findings and how studying negative mechanistic evidence can be helpful in discriminating genuine from spurious results.<\/jats:p>","DOI":"10.1007\/s40656-022-00532-9","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T16:04:36Z","timestamp":1666109076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1979-0746","authenticated-orcid":false,"given":"Mariusz","family":"Maziarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3933-2059","authenticated-orcid":false,"given":"Adrian","family":"Stencel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"issue":"10","key":"532_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4236\/pp.2020.1110022","volume":"11","author":"BG Alani","year":"2020","unstructured":"Alani, B. G., Alwash, A. H., & Ibrahim, I. T. (2020). Wide applications of chloroquine other than antimalarial. Pharmacology & Pharmacy, 11(10), 251\u2013281. https:\/\/doi.org\/10.4236\/pp.2020.1110022","journal-title":"Pharmacology & Pharmacy"},{"issue":"1","key":"532_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/13102818.2020.1847683","volume":"35","author":"R Alexandrova","year":"2021","unstructured":"Alexandrova, R., et al. (2021). The virus that shook the world: Questions and answers about SARS-CoV-2 and COVID-19. Biotechnology & Biotechnological Equipment, 35(1), 74\u2013102. https:\/\/doi.org\/10.1080\/13102818.2020.1847683","journal-title":"Biotechnology & Biotechnological Equipment"},{"issue":"5","key":"532_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1365-2753.2012.01906.x","volume":"18","author":"H Andersen","year":"2012","unstructured":"Andersen, H. (2012). Mechanisms: What are they evidence for in evidence-based medicine? Journal of Evaluation in Clinical Practice, 18(5), 992\u2013999. https:\/\/doi.org\/10.1111\/j.1365-2753.2012.01906.x","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"1","key":"532_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/bmjebm-2018-111092","volume":"25","author":"RL Anjum","year":"2020","unstructured":"Anjum, R. L., Copeland, S., & Rocca, E. (2020). Medical scientists and philosophers worldwide appeal to EBM to expand the notion of \u201cevidence.\u201d BMJ Evidence-Based Medicine, 25(1), 6\u20138. https:\/\/doi.org\/10.1136\/bmjebm-2018-111092","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"3","key":"532_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/jep.13438","volume":"27","author":"JK Aronson","year":"2021","unstructured":"Aronson, J. K., Auker-Howlett, D., Ghiara, V., Kelly, M. P., & Williamson, J. (2021). The use of mechanistic reasoning in assessing coronavirus interventions. Journal of Evaluation in Clinical Practice, 27(3), 684\u2013693. https:\/\/doi.org\/10.1111\/jep.13438","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"532_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijid.2020.06.099","volume":"97","author":"S Arshad","year":"2020","unstructured":"Arshad, S., et al. (2020). Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases, 97, 396\u2013403. https:\/\/doi.org\/10.1016\/j.ijid.2020.06.099","journal-title":"International Journal of Infectious Diseases"},{"issue":"8","key":"532_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews. Drug Discovery, 3(8), 673\u2013683. https:\/\/doi.org\/10.1038\/nrd1468","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"1","key":"532_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological), 57(1), 289\u2013300.","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"},{"issue":"72","key":"532_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/bjps\/axy051","volume":"4","author":"A Bird","year":"2020","unstructured":"Bird, A. (2020). Understanding the replication crisis as a base rate fallacy. The British Journal for the Philosophy of Science, 4(72), 965\u2013993. https:\/\/doi.org\/10.1093\/bjps\/axy051","journal-title":"The British Journal for the Philosophy of Science"},{"key":"532_CR10","doi-asserted-by":"crossref","unstructured":"Blunt, C. J. (2019). The dismal disease: Temozolomide and the interaction of evidence. Retrieved May 7, 2021 from http:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3444926","DOI":"10.2139\/ssrn.3444926"},{"issue":"2","key":"532_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1353\/pbm.0.0086","volume":"52","author":"K Borgerson","year":"2009","unstructured":"Borgerson, K. (2009). Valuing evidence: Bias and the evidence hierarchy of evidence-based medicine. Perspectives in Biology and Medicine, 52(2), 218\u2013233. https:\/\/doi.org\/10.1353\/pbm.0.0086","journal-title":"Perspectives in Biology and Medicine"},{"issue":"6","key":"532_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa2016638","volume":"383","author":"DR Boulware","year":"2020","unstructured":"Boulware, D. R., et al. (2020). A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. New England Journal of Medicine, 383(6), 517\u2013525. https:\/\/doi.org\/10.1056\/NEJMoa2016638","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"532_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1365-2753.2000.00237.x","volume":"6","author":"S Buetow","year":"2000","unstructured":"Buetow, S., & Kenealy, T. (2000). Evidence-based medicine: The need for a new definition\u2019. Journal of Evaluation in Clinical Practice, 6(2), 85\u201392. https:\/\/doi.org\/10.1046\/j.1365-2753.2000.00237.x","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"532_CR201","doi-asserted-by":"crossref","unstructured":"Canali, S. (2019). Evaluating evidential pluralism in epidemiology: Mechanistic evidence in exposome research. History and Philosophy of the Life Sciences, 41(1), 1\u201317.","DOI":"10.1007\/s40656-019-0241-6"},{"issue":"21","key":"532_CR15","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","volume":"383","author":"A Cavalcanti","year":"2020","unstructured":"Cavalcanti, A., et al. (2020). Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine, 383(21), 2041\u20132052. https:\/\/doi.org\/10.1056\/NEJMoa2019014","journal-title":"New England Journal of Medicine"},{"key":"532_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s40656-021-00477-5","volume":"43","author":"A Chellappoo","year":"2021","unstructured":"Chellappoo, A. (2021). Contrasting narratives of race and fatness in Covid-19. HPLS, 43, 120. https:\/\/doi.org\/10.1007\/s40656-021-00477-5","journal-title":"HPLS"},{"key":"532_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.20040758","author":"Z Chen","year":"2020","unstructured":"Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020). Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. MedRxiv. https:\/\/doi.org\/10.1101\/2020.03.22.20040758","journal-title":"MedRxiv"},{"issue":"1","key":"532_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1874297101003010016","volume":"3","author":"RM Christley","year":"2010","unstructured":"Christley, R. M. (2010). Power and error: Increased risk of false positive results in underpowered studies. The Open Epidemiology Journal, 3(1), 16\u201319.","journal-title":"The Open Epidemiology Journal"},{"issue":"6","key":"532_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ypmed.2012.10.020","volume":"57","author":"B Clarke","year":"2013","unstructured":"Clarke, B., et al. (2013). The evidence that evidence-based medicine omits. Preventive Medicine, 57(6), 745\u2013747. https:\/\/doi.org\/10.1016\/j.ypmed.2012.10.020","journal-title":"Preventive Medicine"},{"issue":"2","key":"532_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11245-013-9220-9","volume":"33","author":"B Clarke","year":"2014","unstructured":"Clarke, B., et al. (2014). Mechanisms and the evidence hierarchy. Topoi, 33(2), 339\u2013360. https:\/\/doi.org\/10.1007\/s11245-013-9220-9","journal-title":"Topoi"},{"issue":"1","key":"532_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/157488406775268228","volume":"1","author":"T Cleophas","year":"2006","unstructured":"Cleophas, T., & Zwinderman, A. (2006). Clinical trials are often false positive: A review of simple methods to control this problem. Current Clinical Pharmacology, 1(1), 1\u20134. https:\/\/doi.org\/10.2174\/157488406775268228","journal-title":"Current Clinical Pharmacology"},{"issue":"9360","key":"532_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/s0140-6736(03)12715-8","volume":"361","author":"HM Colhoun","year":"2003","unstructured":"Colhoun, H. M., McKeigue, P. M., & Davey Smith, G. (2003). Problems of reporting genetic associations with complex outcomes. Lancet (London, England), 361(9360), 865\u2013872. https:\/\/doi.org\/10.1016\/s0140-6736(03)12715-8","journal-title":"Lancet (London, England)"},{"issue":"293","key":"532_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/01621459.1961.10482090","volume":"56","author":"OJ Dunn","year":"1961","unstructured":"Dunn, O. J. (1961). Multiple comparisons among means. Journal of the American Statistical Association, 56(293), 52\u201364.","journal-title":"Journal of the American Statistical Association"},{"issue":"1","key":"532_CR24","first-page":"93","volume":"11","author":"P Eze","year":"2021","unstructured":"Eze, P., Mezue, K. N., Nduka, C. U., Obianyo, I., & Egbuche, O. (2021). Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients\u2014A systematic review and meta-analysis of randomized controlled trials. American Journal of Cardiovascular Disease, 11(1), 93.","journal-title":"American Journal of Cardiovascular Disease"},{"issue":"1","key":"532_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cmi.2020.08.022","volume":"27","author":"T Fiolet","year":"2021","unstructured":"Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y. (2021a). Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Clinical Microbiology and Infection, 27(1), 19\u201327.","journal-title":"Clinical Microbiology and Infection"},{"issue":"1","key":"532_CR26","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cmi.2020.08.022","volume":"27","author":"T Fiolet","year":"2021","unstructured":"Fiolet, T., Guihur, A., Rebeaud, M. E., Mulot, M., Peiffer-Smadja, N., & Mahamat-Saleh, Y. (2021b). Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: Authors\u2019 response. Clinical Microbiology and Infection, 27(1), 138. https:\/\/doi.org\/10.1016\/j.cmi.2020.08.022","journal-title":"Clinical Microbiology and Infection"},{"key":"532_CR27","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047","author":"J Gao","year":"2020","unstructured":"Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. https:\/\/doi.org\/10.5582\/bst.2020.01047","journal-title":"Biosci Trends"},{"issue":"8","key":"532_CR28","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1128\/JCM.00636-10","volume":"48","author":"ER Gaunt","year":"2010","unstructured":"Gaunt, E. R., et al. (2010). Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. Journal of Clinical Microbiology, 48(8), 2940\u20132947. https:\/\/doi.org\/10.1128\/JCM.00636-10","journal-title":"Journal of Clinical Microbiology"},{"key":"532_CR29","doi-asserted-by":"crossref","unstructured":"Gautret, P., Lagier, J. C., Parola, P., Meddeb, L., Mailhe, M., Doudier, B., ... Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial.\u00a0International Journal of Antimicrobial Agents,\u00a056(1), 105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"532_CR30","doi-asserted-by":"crossref","unstructured":"Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., ... Schluger, N. W. (2020). Observational study of hydroxychloroquine in hospitalized patients with Covid-19.\u00a0New England Journal of Medicine,\u00a0382(25), 2411\u20132418.","DOI":"10.1056\/NEJMoa2012410"},{"issue":"8","key":"532_CR31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jclinepi.2014.03.012","volume":"67","author":"ME Glickman","year":"2014","unstructured":"Glickman, M. E., Rao, S. R., & Schultz, M. R. (2014). False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. Journal of Clinical Epidemiology, 67(8), 850\u2013857. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.03.012","journal-title":"Journal of Clinical Epidemiology"},{"key":"532_CR32","doi-asserted-by":"publisher","first-page":"m4701","DOI":"10.1136\/bmj.m4701","volume":"371","author":"F Godlee","year":"2020","unstructured":"Godlee, F. (2020). Covid-19: The lost lessons of Tamiflu. BMJ, 371, m4701. https:\/\/doi.org\/10.1136\/bmj.m4701","journal-title":"BMJ"},{"key":"532_CR250","doi-asserted-by":"crossref","unstructured":"Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., De Tribolet, N., Weller, M., & Stupp, R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352(10), 997\u20131003.","DOI":"10.1056\/NEJMoa043331"},{"key":"532_CR33","unstructured":"Hinton. (2020). EUA revoke letter. Retrieved January 7, 2021 from https:\/\/www.fda.gov\/media\/136537\/download"},{"issue":"7826","key":"532_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","volume":"585","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M., et al. (2020). Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature, 585(7826), 588\u2013590. https:\/\/doi.org\/10.1038\/s41586-020-2575-3","journal-title":"Nature"},{"issue":"5","key":"532_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/jep.13443","volume":"26","author":"B Hofmann","year":"2020","unstructured":"Hofmann, B. (2020). The first casualty of an epidemic is evidence. Journal of Evaluation in Clinical Practice, 26(5), 1344\u20131346. https:\/\/doi.org\/10.1111\/jep.13443","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"532_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/frma.2021.600706","volume":"6","author":"B Holman","year":"2021","unstructured":"Holman, B. (2021). What, me worry? Research policy and the open embrace of industry-academic relations. Frontiers in Research Metrics and Analytics, 6, 31.","journal-title":"Frontiers in Research Metrics and Analytics"},{"issue":"21","key":"532_CR37","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"P Horby","year":"2020","unstructured":"Horby, P., et al. (2020). Effect of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine, 383(21), 2030\u20132040.","journal-title":"New England Journal of Medicine"},{"key":"532_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/9781444342673","volume-title":"The philosophy of evidence-based medicine","author":"JH Howick","year":"2011","unstructured":"Howick, J. H. (2011). The philosophy of evidence-based medicine. Wiley."},{"issue":"1","key":"532_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cell.2020.08.028","volume":"183","author":"C Iadecola","year":"2020","unstructured":"Iadecola, C., Anrather, J., & Kamel, H. (2020). Effects of COVID-19 on the nervous system. Cell, 183(1), 16-27.e1. https:\/\/doi.org\/10.1016\/j.cell.2020.08.028","journal-title":"Cell"},{"issue":"2","key":"532_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/02698595.2011.574856","volume":"25","author":"PM Illari","year":"2011","unstructured":"Illari, P. M. (2011). Mechanistic evidence: Disambiguating the Russo-Williamson thesis. International Studies in the Philosophy of Science, 25(2), 139\u2013157.","journal-title":"International Studies in the Philosophy of Science"},{"key":"532_CR41","first-page":"62","volume-title":"The Routledge companion to philosophy of medicine","author":"P Illari","year":"2016","unstructured":"Illari, P. (2016). Mechanisms in medicine. The Routledge companion to philosophy of medicine (pp. 62\u201371). Routledge."},{"issue":"8","key":"532_CR42","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JPA Ioannidis","year":"2005","unstructured":"Ioannidis, J. P. A. (2005). Why most published research findings are false. PLOS Medicine, 2(8), e124. https:\/\/doi.org\/10.1371\/journal.pmed.0020124","journal-title":"PLOS Medicine"},{"issue":"1","key":"532_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jinf.2010.10.003","volume":"62","author":"RJ Jackson","year":"2011","unstructured":"Jackson, R. J., et al. (2011). Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review. The Journal of Infection, 62(1), 14\u201325. https:\/\/doi.org\/10.1016\/j.jinf.2010.10.003","journal-title":"The Journal of Infection"},{"key":"532_CR44","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.12688\/f1000research.26707.2","volume":"9","author":"P Janiaud","year":"2020","unstructured":"Janiaud, P., et al. (2020). The worldwide clinical trial research response to the COVID-19 pandemic\u2014The first 100 days. F1000Research, 9, 1193. https:\/\/doi.org\/10.12688\/f1000research.26707.2","journal-title":"F1000Research"},{"issue":"2","key":"532_CR45","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/jmv.26443","volume":"93","author":"Y Jiang","year":"2021","unstructured":"Jiang, Y., et al. (2021). Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis. Journal of Medical Virology,\u00a093(2), 1171\u20131174. https:\/\/doi.org\/10.1002\/jmv.26443","journal-title":"Journal of Medical Virology."},{"issue":"10","key":"532_CR46","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/sim.5634","volume":"32","author":"M Kieser","year":"2013","unstructured":"Kieser, M., Friede, T., & Gondan, M. (2013). Assessment of statistical significance and clinical relevance. Statistics in Medicine, 32(10), 1707\u20131719. https:\/\/doi.org\/10.1002\/sim.5634","journal-title":"Statistics in Medicine"},{"key":"532_CR47","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2959","author":"SE Kimmel","year":"2020","unstructured":"Kimmel, S. E., et al. (2020). COVID-19 clinical trials: A teachable moment for improving our research infrastructure and relevance. Annals of Internal Medicine. https:\/\/doi.org\/10.7326\/M20-2959","journal-title":"Annals of Internal Medicine"},{"key":"532_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jmp\/jhp034","volume-title":"Evidence-based medicine must be \u2026. SSRN Scholarly Paper ID 1468207","author":"A La Caze","year":"2009","unstructured":"La Caze, A. (2009). Evidence-based medicine must be \u2026. SSRN Scholarly Paper ID 1468207. Rochester: Social Science Research Network. https:\/\/doi.org\/10.1093\/jmp\/jhp034"},{"key":"532_CR251","doi-asserted-by":"crossref","unstructured":"La Caze, A. (2011). The role of basic science in evidence-based medicine. Biology & Philosophy, 26(1), 81\u201398.","DOI":"10.1007\/s10539-010-9231-5"},{"issue":"11","key":"532_CR49","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nrmicro3351","volume":"12","author":"SB Laskey","year":"2014","unstructured":"Laskey, S. B., & Siliciano, R. F. (2014). A mechanistic theory to explain the efficacy of antiretroviral therapy. Nature Reviews. Microbiology, 12(11), 772\u2013780. https:\/\/doi.org\/10.1038\/nrmicro3351","journal-title":"Nature Reviews. Microbiology."},{"issue":"6","key":"532_CR50","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/cts.12860","volume":"13","author":"M Lauriola","year":"2020","unstructured":"Lauriola, M., et al. (2020). Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in patients with COVID-19. Clinical and Translational Science, 13(6), 1071\u20131076. https:\/\/doi.org\/10.1111\/cts.12860","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"532_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu, J., et al. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6(1), 1\u20134. https:\/\/doi.org\/10.1038\/s41421-020-0156-0","journal-title":"Cell Discovery."},{"key":"532_CR56","doi-asserted-by":"publisher","first-page":"m1844","DOI":"10.1136\/bmj.m1844","volume":"369","author":"M Mah\u00e9vas","year":"2020","unstructured":"Mah\u00e9vas, M., et al. (2020). Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. British Medical Journal, 369, m1844.","journal-title":"British Medical Journal"},{"key":"532_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.shpsa.2018.08.003","volume":"73","author":"C Marchionni","year":"2019","unstructured":"Marchionni, C., & Reijula, S. (2019). What is mechanistic evidence, and why do we need it for evidence-based policy? Studies in History and Philosophy of Science Part A, 73, 54\u201363.","journal-title":"Studies in History and Philosophy of Science Part A"},{"key":"532_CR220","doi-asserted-by":"publisher","unstructured":"Martinez, M., & Teira, D. (2020). Why experimental balance is still a reason to randomize. The British Journal for the Philosophy of Science. First View. https:\/\/doi.org\/10.1086\/716096","DOI":"10.1086\/716096"},{"key":"532_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijid.2020.09.1470","volume":"101","author":"F Mazhar","year":"2020","unstructured":"Mazhar, F., Hadi, M. A., Kow, C. S., Marran, A. M. N., Merchant, H. A., & Hasan, S. S. (2020). Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? International Journal of Infectious Diseases, 101, 107\u2013120.","journal-title":"International Journal of Infectious Diseases."},{"issue":"3","key":"532_CR59","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/jep.13394","volume":"26","author":"M Mercuri","year":"2020","unstructured":"Mercuri, M. (2020). Don\u2019t panic, it is only an emergency. Journal for Evaluation in Clinical Practice, 26(3), 685\u2013686. https:\/\/doi.org\/10.1111\/jep.13394","journal-title":"Journal for Evaluation in Clinical Practice."},{"key":"532_CR60","doi-asserted-by":"crossref","unstructured":"Million, M., Gautret, P., Colson, P., Roussel, Y., Dubourg, G., Chabriere, E., ... Raoult, D. (2020). Clinical efficacy of chloroquine derivatives in COVID-19 infection: Comparative meta-analysis between the big data and the real world.\u00a0New Microbes and New Infections,\u00a038, 100709.","DOI":"10.1016\/j.nmni.2020.100709"},{"issue":"384","key":"532_CR61","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa2021801","volume":"5","author":"O Mitj\u00e0","year":"2020","unstructured":"Mitj\u00e0, O., et al. (2020). A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. New England Journal of Medicine, 5(384), 417\u2013427. https:\/\/doi.org\/10.1056\/NEJMoa2021801","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"532_CR62","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","volume":"181","author":"V Monteil","year":"2020","unstructured":"Monteil, V., Kwon, H., Prado, P., et al. (2020). Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell, 181(4), 905\u2013913. https:\/\/doi.org\/10.1016\/j.cell.2020.04.004","journal-title":"Cell"},{"key":"532_CR63","unstructured":"National Institute for Health and Care Excellence. (2014). Developing NICE guidelines: The manual. Retrieved January 12, 2020 from https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/"},{"issue":"1","key":"532_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drudis.2018.06.012","volume":"24","author":"A Neuberger","year":"2019","unstructured":"Neuberger, A., Oraiopoulos, N., & Drakeman, D. L. (2019). Renovation as innovation: Is repurposing the future of drug discovery research? Drug Discovery Today, 24(1), 1\u20133. https:\/\/doi.org\/10.1016\/j.drudis.2018.06.012","journal-title":"Drug Discovery Today"},{"key":"532_CR65","unstructured":"Oxford Centre for Evidence-Based Medicine. (2009). The Oxford 2009 levels of evidence. Retrieved February 21, 2021 from https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/"},{"key":"532_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-94610-8","volume-title":"Evaluating evidence of mechanisms in medicine: Principles and procedures","author":"V-P Parkkinen","year":"2018","unstructured":"Parkkinen, V.-P., et al. (2018). Evaluating evidence of mechanisms in medicine: Principles and procedures. Springer."},{"key":"532_CR67","doi-asserted-by":"publisher","first-page":"118275","DOI":"10.1016\/j.lfs.2020.118275","volume":"259","author":"V Parvathaneni","year":"2020","unstructured":"Parvathaneni, V., & Gupta, V. (2020). Utilizing drug repurposing against COVID-19\u2014Efficacy, limitations, and challenges. Life Sciences, 259, 118275. https:\/\/doi.org\/10.1016\/j.lfs.2020.118275","journal-title":"Life Sciences"},{"issue":"1","key":"532_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cmi.2020.10.011","volume":"27","author":"M Paul","year":"2021","unstructured":"Paul, M. (2021). Has the door closed on hydroxychloroquine for SARS-COV-2? Clinical Microbiology and Infection, 27(1), 3\u20135.","journal-title":"Clinical Microbiology and Infection"},{"key":"532_CR69","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","volume":"316","author":"TV Perneger","year":"1998","unstructured":"Perneger, T. V. (1998). What\u2019s wrong with Bonferroni adjustments. British Medical Journal, 316, 1236\u20131238.","journal-title":"British Medical Journal"},{"key":"532_CR210","unstructured":"P\u00f6hlmann, S. (2020). Malaria drug chloroquine does not inhibit SARS-CoV-2. Retrieved from: https:\/\/www.dpz.eu\/en\/info-center\/40th-anniversary-of-the-dpz\/einzelansicht\/news\/malaria-medikamentchloroquin-hemmt-sars-cov-2-nicht.html"},{"issue":"1","key":"532_CR71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S., et al. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nature Reviews Drug Discovery"},{"key":"532_CR72","doi-asserted-by":"publisher","first-page":"173926","DOI":"10.1016\/j.ejphar.2021.173926","volume":"897","author":"A Rezagholizadeh","year":"2021","unstructured":"Rezagholizadeh, A., Khiali, S., Sarbakhsh, P., & Entezari-Maleki, T. (2021). Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. European Journal of Pharmacology, 897, 173926.","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"532_CR73","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/jep.12994","volume":"24","author":"E Rocca","year":"2018","unstructured":"Rocca, E. (2018). The judgements that evidence-based medicine adopts. Journal of Evaluation in Clinical Practice, 24(5), 1184\u20131190. https:\/\/doi.org\/10.1111\/jep.12994","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"4","key":"532_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","volume":"30","author":"J-M Rolain","year":"2007","unstructured":"Rolain, J.-M., Colson, P., & Raoult, D. (2007). Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International Journal of Antimicrobial Agents, 30(4), 297\u2013308. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.05.015","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"1","key":"532_CR75","doi-asserted-by":"publisher","first-page":"106063","DOI":"10.1016\/j.ijantimicag.2020.106063","volume":"56","author":"FR Rosendaal","year":"2020","unstructured":"Rosendaal, F. R. (2020). Review of: Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial Gautret et al 2010. International Journal of Antimicrobial Agents, 56(1), 106063.","journal-title":"International Journal of Antimicrobial Agents"},{"key":"532_CR76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","volume":"1","author":"KJ Rothman","year":"1990","unstructured":"Rothman, K. J. (1990). No adjustments are needed for multiple comparisons. Epidemiology, 1, 43\u201346.","journal-title":"Epidemiology"},{"issue":"3","key":"532_CR77","doi-asserted-by":"publisher","first-page":"10969","DOI":"10.1007\/s11229-021-03276-4","volume":"199","author":"M Rubin","year":"2021","unstructured":"Rubin, M. (2021). When to adjust alpha during multiple testing: A consideration of disjunction, conjunction, and individual testing. Synthese, 199(3), 10969\u201311000.","journal-title":"Synthese"},{"issue":"2","key":"532_CR78","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/02698590701498084","volume":"21","author":"F Russo","year":"2007","unstructured":"Russo, F., & Williamson, J. (2007). Interpreting causality in the health sciences. International Studies in the Philosophy of Science, 21(2), 157\u2013170. https:\/\/doi.org\/10.1080\/02698590701498084","journal-title":"International Studies in the Philosophy of Science"},{"key":"532_CR79","volume-title":"Evidence-based medicine: How to practice and teach EBM","author":"DL Sackett","year":"2000","unstructured":"Sackett, D. L., et al. (2000). Evidence-based medicine: How to practice and teach EBM (2nd ed.). Churchill Livingstone.","edition":"2"},{"key":"532_CR300","unstructured":"Samuels, E. & Kelly, M. (2020). How false hope spread about hydroxychloroquine to treat COVID-19 - and the concequences that followed. The Washington Post. Retrieved from https:\/\/www.washingtonpost.com\/politics\/2020\/04\/13\/how-false-hopespread-about-hydroxychloroquine-its-consequences\/"},{"issue":"18","key":"532_CR80","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2020.6019","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., et al. (2020). Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA, 323(18), 1824\u20131836. https:\/\/doi.org\/10.1001\/jama.2020.6019","journal-title":"JAMA"},{"key":"532_CR81","doi-asserted-by":"publisher","first-page":"e4960","DOI":"10.1136\/bmj.e4960","volume":"345","author":"P Sedgwick","year":"2012","unstructured":"Sedgwick, P. (2012). Confidence intervals and statistical significance: Rules of thumb. BMJ, 345, e4960. https:\/\/doi.org\/10.1136\/bmj.e4960","journal-title":"BMJ"},{"key":"532_CR82","doi-asserted-by":"crossref","unstructured":"Self, W. H., Semler, M. W., Leither, L. M., Casey, J. D., Angus, D. C., Brower, R. G., ... Brown, S. M. (2020). Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: A randomized clinical trial.\u00a0JAMA,\u00a0324(21), 2165\u20132176.","DOI":"10.1001\/jama.2020.22240"},{"key":"532_CR83","doi-asserted-by":"publisher","DOI":"10.4155\/fdd-2020-0010","author":"SL Senanayake","year":"2020","unstructured":"Senanayake, S. L. (2020). Drug repurposing strategies for COVID-19. Future Drug Discovery. https:\/\/doi.org\/10.4155\/fdd-2020-0010","journal-title":"Future Drug Discovery"},{"issue":"4","key":"532_CR85","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.dsx.2020.05.017","volume":"14","author":"AK Singh","year":"2020","unstructured":"Singh, A. K., Singh, A., Singh, R., & Misra, A. (2020). Hydroxychloroquine in patients with COVID-19: A systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14(4), 589\u2013596.","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"issue":"3","key":"532_CR86","doi-asserted-by":"publisher","first-page":"434","DOI":"10.7326\/L20-1426","volume":"174","author":"CP Skipper","year":"2021","unstructured":"Skipper, C. P., & Boulware, D. R. (2021). Hydroxychloroquine in nonhospitalized adults with early COVID-19. Annals of Internal Medicine, 174(3), 434\u2013435.","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"532_CR87","doi-asserted-by":"publisher","first-page":"267","DOI":"10.14740\/cr1140","volume":"11","author":"J Somberg","year":"2020","unstructured":"Somberg, J. (2020). Science, politics and hydroxychloroquine. Cardiology Research, 11(5), 267.","journal-title":"Cardiology Research"},{"issue":"4","key":"532_CR88","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.shpsc.2011.07.003","volume":"42","author":"J Stegenga","year":"2011","unstructured":"Stegenga, J. (2011). Is meta-analysis the platinum standard of evidence? Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, 42(4), 497\u2013507.","journal-title":"Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences"},{"key":"532_CR89","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198747048.003.0011","volume-title":"Medical nihilism","author":"J Stegenga","year":"2018","unstructured":"Stegenga, J. (2018). Medical nihilism. Oxford University Press."},{"issue":"3\u20134","key":"532_CR91","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jnci\/88.3-4.206","volume":"88","author":"IF Tannock","year":"1996","unstructured":"Tannock, I. F. (1996). False-positive results in clinical trials: Multiple significance tests and the problem of unreported comparisons. JNCI: Journal of the National Cancer Institute, 88(3\u20134), 206\u2013207. https:\/\/doi.org\/10.1093\/jnci\/88.3-4.206","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"264","key":"532_CR93","first-page":"624","volume":"48","author":"J Tukey","year":"1953","unstructured":"Tukey, J. (1953). Multiple comparisons. Journal of the American Statistical Association, 48(264), 624\u2013625.","journal-title":"Journal of the American Statistical Association"},{"key":"532_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013600","author":"SJ Valk","year":"2020","unstructured":"Valk, S. J., et al. (2020). Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A rapid review. Cochrane Database of Systematic Reviews. https:\/\/doi.org\/10.1002\/14651858.CD013600","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"532_CR95","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12874-019-0865-y","volume":"19","author":"D van Ravenzwaaij","year":"2019","unstructured":"van Ravenzwaaij, D., & Ioannidis, J. P. A. (2019). True and false positive rates for different criteria of evaluating statistical evidence from clinical trials. BMC Medical Research Methodology, 19(1), 218. https:\/\/doi.org\/10.1186\/s12874-019-0865-y","journal-title":"BMC Medical Research Methodology"},{"issue":"6","key":"532_CR96","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jnci\/djh075","volume":"96","author":"S Wacholder","year":"2004","unstructured":"Wacholder, S., et al. (2004). Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. JNCI: Journal of the National Cancer Institute, 96(6), 434\u2013442. https:\/\/doi.org\/10.1093\/jnci\/djh075","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"532_CR98","doi-asserted-by":"crossref","unstructured":"Wang, Z., Zheutlin, A., Kao, Y. H., Ayers, K., Gross, S., Kovatch, P., ... Li, L. (2020). Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.\u00a0BMJ Open,\u00a010(10), e040441.","DOI":"10.1136\/bmjopen-2020-040441"},{"issue":"6","key":"532_CR99","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2021","unstructured":"WHO Solidarity Trial Consortium. (2021). Repurposed antiviral drugs for Covid-19\u2014Interim WHO solidarity trial results. New England Journal of Medicine, 384(6), 497\u2013511. https:\/\/doi.org\/10.1056\/NEJMoa2023184","journal-title":"New England Journal of Medicine"},{"key":"532_CR205","doi-asserted-by":"crossref","unstructured":"Williamson, J. (2019). Establishing causal claims in medicine. International Studies in the Philosophy of Science, 32(1), 33\u201361.","DOI":"10.1080\/02698595.2019.1630927"},{"issue":"2","key":"532_CR100","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1365-2753.2010.01400.x","volume":"16","author":"J Worrall","year":"2010","unstructured":"Worrall, J. (2010). Evidence: Philosophy of science meets medicine. Journal of Evaluation in Clinical Practice, 16(2), 356\u2013362. https:\/\/doi.org\/10.1111\/j.1365-2753.2010.01400.x","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"15","key":"532_CR101","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","volume":"71","author":"X Yao","year":"2020","unstructured":"Yao, X., et al. (2020). In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, 71(15), 732\u2013739. https:\/\/doi.org\/10.1093\/cid\/ciaa237","journal-title":"Clinical Infectious Diseases"}],"container-title":["History and Philosophy of the Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40656-022-00532-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40656-022-00532-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40656-022-00532-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T15:14:17Z","timestamp":1672154057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40656-022-00532-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1007\/s40656-022-00532-9","relation":{},"ISSN":["0391-9714","1742-6316"],"issn-type":[{"value":"0391-9714","type":"print"},{"value":"1742-6316","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"27 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors reports conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"47"}}